PV Bulletin

Use of AI in GXP Inspection Responses

MHRA guidance emphasizes accuracy in AI-generated responses to inspections, impacting workflows.

Primary source: Medicines and Healthcare products Regulatory Agency (MHRA)

PV Impact Brief

Urgency: HighConfidence: high

What changed

Organizations must implement quality checks for AI-generated content used in responses to ensure factual accuracy and compliance with MHRA standards.

Why it matters

Inaccurate information in submissions may lead to delays, increased scrutiny, or rejection of responses, placing a strain on resources and regulatory compliance.

Action needed

Implement mandatory quality checks and oversight for all AI-generated inspection responses to meet MHRA expectations for accuracy.

Relevant for
Regulatory Intelligence LeadPV Quality Lead
Processes impacted
Inspection ReadinessCAPA
Owner

Regulatory Intelligence Lead

Review cadence

Review in the next regulatory intelligence cycle.

Policy change details

Document type
Guidance / Notice
Policy status
effective
Publication date
2026-06-29
Policy change
MHRA guidance published on the Inspectorate Blog regarding the use of Artificial Intelligence (AI) when drafting responses to GxP inspection findings.

Key changes

Establishes expectations for the use of AI in regulatory communications. Emphasizes that MAHs and sponsors are fully responsible for the accuracy of AI-generated content and warns against inaccuracies or 'hallucinations' in inspection responses.

Affected workflows

Inspection ReadinessCAPA

Responsible groups

Quality AssurancePV QualityCompliance Team

PV impact

Impacts inspection readiness and CAPA workflows. Organizations using AI for drafting responses must implement quality checks to ensure citations and factual claims are accurate to avoid regulatory non-compliance.

View regulator source

Source document details

Exact policy details

Responsibility for Accuracy
Organizations must ensure the accuracy of their submissions to the MHRA.
Applies to: All organizations submitting responses to MHRA.
Organisations have always been responsible for the accuracy of their responses to the MHRA and persons responsible for them have always been expected to verify factual claims. · p. 1 · High · Source
Expectations for Submission Accuracy
All submissions/responses must be factually accurate and verifiable.
Applies to: Applicable to all submissions to MHRA Compliance Teams.
All submissions/responses must be: factually accurate and verifiable. · p. 1 · High · Source
Impact of Inaccurate Information
Inaccurate submissions may lead to rejection or request for resubmission.
Applies to: Responses to MHRA inspections.
if the information supplied in response to an inspection is inaccurate, incomplete or overly verbose then we may reject the response or return it for another attempt. · p. 1 · High · Source
Disclosure of AI Use
Organizations can voluntarily disclose AI use in submissions.
Applies to: Applicable to organizations using AI in responses.
we are offering organisations the option to disclose AI use in responses/submissions to the compliance teams. · p. 1 · High · Source

Workflow rule impacts

Inspection ReadinessCompliance Teams

Increased scrutiny of submissions and potential resource strain if AI tools are misused.

Expectations for accuracy and oversight are higher due to AI tool usage.

As AI becomes more sophisticated, this framework remains relevant because it focuses on accountability and process. · p. 1 · High · Source

Evidence and confidence

Confidence: highSource updated: Jun 29, 2026

Full briefing

Practical implication

Implement mandatory quality checks and oversight for all AI-generated inspection responses to meet MHRA expectations for accuracy.

The MHRA has released guidance on the use of AI in drafting responses to GxP inspection findings. It underscores that organizations are fully accountable for the accuracy of AI-generated content, warning against inaccuracies that could lead to regulatory non-compliance. The guidance includes higher expectations for submission accuracy due to the use of AI, impacting inspection readiness and corrective action preventive action (CAPA) processes.

What changed: Organizations must implement quality checks for AI-generated content used in responses to ensure factual accuracy and compliance with MHRA standards.

Why it matters: Inaccurate information in submissions may lead to delays, increased scrutiny, or rejection of responses, placing a strain on resources and regulatory compliance.

Practical implication: Implement mandatory quality checks and oversight for all AI-generated inspection responses to meet MHRA expectations for accuracy.

View original source

Published from the Firecrawl policy change extraction pipeline.

Related updates for your role

publicFDA · United States · Updated Aug 17, 2026

Revised FDA Guidance on ANDA and 505(b)(2) Application Submission

Urgency: High

Implement a gap analysis for 505(b)(2) applications to identify safety data needs and adjust safety monitoring systems as necessary to accommodate new product characteristics.

Country ComplianceRegulatory Intelligence Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, QPPV
verifiedRegulatory action: Draft Guidance
Read impact briefarrow_forward
publicMedicines and Healthcare products Regulatory Agency (MHRA) · United Kingdom · Updated Aug 18, 2026

UK Position Paper on Microbiome-Based Medicinal Products (MBMPs)

Urgency: High

MAHs and sponsors must enhance their pharmacovigilance systems to monitor microbiome-specific safety issues, comply with established safety standards, and address concerns related to antimicrobial resistance.

Signal ManagementCountry ComplianceRegulatory Intelligence Lead
SOP Impact2 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, Signal Management Lead, QPPV
verifiedRegulatory action: Position Paper
Read impact briefarrow_forward
publicU.S. Food and Drug Administration · United States · Updated Aug 18, 2026

Regulatory Framework for Generative AI-Enabled Medical Devices

Urgency: High

Stakeholders, including manufacturers and clinicians, must review and potentially revise their post-market vigilance and safety monitoring protocols in response to the FDA's proposed regulatory approaches for generative AI devices.

Signal ManagementICSRRegulatory Intelligence Lead
SOP Impact2 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, Signal Management Lead, QPPV
verifiedRegulatory action: Notice
Read impact briefarrow_forward
publicMHRA · United Kingdom · Updated Aug 18, 2026

MHRA Clarifies Regulatory Pathways for Microbiome-Based Medicinal Products

Urgency: High

Developers of MBMPs must align their safety assessment protocols with the MHRA's expectations and are encouraged to engage with the MHRA early to establish appropriate regulatory strategies.

Literature SurveillanceCountry ComplianceRegulatory Intelligence Lead
SOP Impact2 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, QPPV
verifiedRegulatory action: Notice / Position Paper
Read impact briefarrow_forward